IHL.AX stock leads pre-market activity on the ASX, trading at A$0.041 on 61,360,016 shares as of this session. The Incannex Healthcare Limited (IHL.AX) move follows renewed interest in its clinical pipeline and a large intraday block that pushed volume to roughly 9.55x average. We outline drivers, valuation metrics and a model forecast to frame trading risk in this most-active pre-market name.
Pre-market trading snapshot for IHL.AX stock
Incannex Healthcare Limited (IHL.AX) opened at A$0.047 and is trading at A$0.041 after a -10.87% move. Volume stands at 61,360,016 versus average 6,427,691, giving a relative volume of 9.55 which flags outsized interest. The stock sits at its one-year low of A$0.041 and is well below the 50-day average of A$0.0649 and the 200-day average of A$0.10285.
Catalysts and recent news affecting IHL.AX
Market attention follows clinical updates and coverage on the company’s IHL-42X and other candidates. A recent note referenced by Seeking Alpha highlights IHL-42X’s Phase 2/3 status and renewed investor focus source. Incannex’s corporate site lists the full pipeline and trial status, supporting the clinical-news-driven volume source.
IHL.AX stock financials and valuation
Incannex reports EPS of -1.30 and a negative PE ratio, shown as -0.03, reflecting pre-revenue biotech economics. Market cap is A$14,255,927.00 with shares outstanding 347,705,540, and book value per share is A$0.05474. Key ratios include price-to-book 0.75 and price-to-sales 14.06, signalling valuation compressed to balance sheet assets and R&D exposure.
Technical and liquidity signals for IHL.AX stock
Price momentum is negative with the close below both the 50-day and 200-day averages, a bearish technical profile. However, the 61,360,016 volume spike lifts liquidity and increases short-term volatility, evident in a 1M decline of 10.87% and a 3M decline near 46.75%. Traders should note high bid-ask risk at sub-cent price levels on the ASX in AUD.
Meyka grade, model forecast and analyst framing
Meyka AI rates IHL.AX with a score out of 100: 60.99 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month base target of A$0.070, implying an upside of 70.73% versus the current A$0.041. Forecasts are model-based projections and not guarantees.
Final Thoughts
IHL.AX stock is the ASX’s most active pre-market name today because of unusually large volume and renewed attention on its drug pipeline. The company shows classic early-stage biotech metrics: negative EPS at -1.30, a negative PE, and a market cap of A$14,255,927.00, while balance-sheet ratios like price-to-book 0.75 provide partial support. Technically, the stock trades below both the 50-day A$0.0649 and the 200-day A$0.10285 averages, keeping the short-term trend bearish. Our model assigns a base 12-month forecast of A$0.070, a conservative target of A$0.050 and a bull scenario of A$0.120, with implied moves of +70.73%, +21.95%, and +192.68% respectively versus the current A$0.041. These figures reflect scenario-based outcomes linked to clinical milestones and funding events. Use Meyka AI’s data as one input among many, and remember forecasts are projections, not guarantees.
FAQs
What is the current price of IHL.AX stock?
IHL.AX stock trades at A$0.041 in this pre-market session. The stock opened at A$0.047 and has a one-year low at A$0.041 with heavy volume of 61,360,016 shares.
What valuation metrics matter for IHL.AX stock?
Key metrics: EPS -1.30, PE negative (-0.03), price-to-book 0.75, and price-to-sales 14.06. These show early-stage R&D risk and reliance on funding rather than operating revenue.
What forecast does Meyka AI give for IHL.AX stock?
Meyka AI’s forecast model projects a 12-month base target of A$0.070, implying +70.73% versus the current A$0.041. Forecasts are model-based and not guarantees.
What are the main risks for IHL.AX stock investors?
Primary risks include trial setbacks, cash runway, regulatory delays, and high trading volatility. The company has negative earnings, limited revenues, and small market cap, increasing binary event risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)